Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-0260-2021

Drug recall · February 24, 2021

Auryxia recall

Why: Failed Dissolution Specifications

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Auryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., 245 First Street, Suite 1400, Cambridge, MA 02142, USA, NDC 59922-0631-01.

Lots / codes

Lots #: CDKSN, CDPPH, Exp January 2022; Lot #: CDPPK, Exp February 2022.

Quantity
17,664 bottles
Company
Akebia Therapeutics dba Keryx Biopharmaceutials, Inc, Cambridge, MA
Distribution
Nationwide.
Initiated
January 29, 2021 · Voluntary: Firm initiated
Classified
February 17, 2021
Reported
February 24, 2021
Ended
February 10, 2022
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Auryxia

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.